February 15, 2026 – Patient Worthy

CHMP Backs Novo Nordisk’s Semaglutide for MASH, Opening Door to EU Approval

Post author:Austin Newman
Post published:February 15, 2026
Post category:Metabolic dysfunction-associated steatohepatitis

As reported on MedicalXpress, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for several therapies this cycle, including a conditional endorsement…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More